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Fukutin-related protein (FKRP; OMIM #606596) muscular dystro-
phies are autosomal recessive disorders caused by mutations 
that occur in the FKRP gene. They may be misdiagnosed as 
dystrophinopathies because they have overlapping clinical features. 
Mutations in the coding exon of FKRP cause both merosin-deficient 
congenital muscular dystrophy type 1C (MDC1C) and limb-girdle 
muscular dystrophy type 2I (LGMD2I).[1-3] MDC1C represents 
a more severe phenotype, while LGMD2I is the milder allelic 
version.[1] Duchenne’s muscular dystrophy (DMD; OMIM #310200) 
and Becker’s muscular dystrophy (BMD; OMIM #300376), grouped 
together as dystrophinopathies, are both X-linked recessive disorders 
involving the proximal skeletal muscles. Dystrophinopathies are 
caused by mutations in the dystrophin gene, leading to complete 
inactivation (DMD) or partial inactivation (BMD) of this gene.[4]
The FKRP gene maps to the cytogenetic region 19q13.32 between 
the markers D19S219 and D19S606. It is composed of four exons and 
spans 12.53 kb. Exon 4, which is the largest and the only coding exon 
in this gene, contains a portion of the 5ʹ untranslated region (UTR), 
as well as the entire protein coding region and the complete 3ʹ UTR. 
The FKRP gene encodes a 495 amino acid protein known as the 
fukutin-related protein (FKRP).[5]
Founder mutations occur in populations that originate from a 
small number of individuals and undergo a period of rapid growth. 
The Afrikaner population of South Africa (SA) has many features 
of a founder population. The term ‘Afrikaners’ refers to a subset 
of white SA individuals who are descended from a small group of 
German, Dutch and Huguenot settlers who immigrated to the Cape 
of Good Hope in the 1600s.[6] It is difficult to distinguish Afrikaner 
individuals from other South Africans of European ancestry, and 
usually surnames, as well as the use of Afrikaans as a first language, 
are used to broadly define an Afrikaner individual. There are many 
diseases for which founder mutations have been described in the 
Afrikaner population. Some of these include Fanconi’s anaemia, 
porphyria variegata, familial hypercholesterolaemia, Gaucher’s dis-
ease and autosomal recessive polycystic kidney disease.[7-11]
FKRP founder mutations have been described in a number 
of populations around the world, for example the c.826C>A 
(p.Leu276Ile) FKRP mutation in 20 LGMD German patients[12]  
as well as 13 LGMD patients from Denmark,[13] and a novel 
homozygous missense mutation, c.1364C>A (p.Ala455Asp), in 
Tunisian families.[14] A previously unreported mutation, c.1100T>C 
(p.Ile367Thr), was found in homozygous form in the FKRP gene 
in two unrelated SA white patients of Afrikaner origin clinically 
diagnosed with a dystrophinopathy in 2010 by the Genetics Centre 
at Guy’s Hospital in London, and a founder mutation was therefore 
suspected.
Objectives
To screen for the c.1100T>C and the common European c.826C>A 
FKRP-related muscular dystrophy mutations in white SA Afrikaner 
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Background. Fukutin-related protein (FKRP) muscular dystrophy is an autosomal recessive disorder caused by mutations in the FKRP 
gene. The condition is often misdiagnosed as a dystrophinopathy. A previously unreported mutation, c.1100T>C in exon 4 of FKRP, had 
been identified in homozygous form in two white South African (SA) Afrikaner patients clinically diagnosed with a dystrophinopathy.
Objectives. To investigate whether the c.1100T>C mutation and the common European FKRP mutation c.826C>A are present in other 
patients of Afrikaner origin with suspected dystrophinopathy, and whether a founder haplotype exists.
Methods. The c.1100T>C mutation was initially tested for using an amplification refractory mutation system technique in 45 white SA 
Afrikaner patients who had tested negative using multiplex ligation probe amplification screening for exonic deletions/duplications in the 
dystrophin gene. Sequencing analysis was used to confirm the c.1100T>C mutation and screen for the c.826C>A mutation. Two cohorts 
(each numbering 100) of Afrikaans and other white controls were screened for the c.1100T>C and c.826C>A mutations, respectively.
Results. Of the 45 patients, 8 patients (17.8%) were homozygous for c.1100T>C, 2 (4.4%) were compound heterozygotes for c.1100T>C 
and c.826C>A, and 1 (2.2%) was heterozygous for c.1100T>C with a second unidentified mutation. The c.1100T>C mutation was found in 
1/100 controls, but no heterozygotes for the c.826C>A mutation were identified. Linked marker analysis for c.1100T>C showed a common 
haplotype, suggesting a probable founder mutation in the SA Afrikaner population.
Conclusion. FKRP mutations may be relatively common in Afrikaners, and screening should be considered in patients who have a 
suggestive phenotype and test negative for a dystrophinopathy. This test will be useful for offering diagnostic, carrier and prenatal testing 
for affected individuals and their families. As FKRP muscular dystrophy is autosomal recessive in inheritance, the implications of a positive 
diagnosis in a family differ significantly from those of an X-linked dystrophinopathy.
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patients who were referred for dystrophinopathy testing but tested 
negative for deletions or duplications in the dystrophin gene. 
The specific objectives were to determine whether SA Afrikaner 
patients clinically diagnosed with a phenotype suggestive of a 
dystrophinopathy and negative for dystrophin mutations have 
the c.1100T>C and c.826C>A FKRP mutations, and whether the 
c.1100T>C mutation is a founder mutation in the SA Afrikaner 
population based on the presence of a common haplotype.
Subjects
Patients
A total of 45 white SA patients of Afrikaner origin (based on their 
surnames) were included in this study. The patients were routine 
referrals to the Division of Human Genetics, National Health 
Laboratory Service (NHLS), for dystrophinopathy diagnostic testing 
from 1994 to 2013 and who tested negative for exonic deletions/
duplications on multiplex ligation probe amplification (MLPA) 
screening using SALSA MLPA kits and P034 and P035 probe 
mixes (MRC-Holland, Netherlands). Patients with a family history 
suggestive of an X-linked pattern of disease were excluded.
The majority of referrals were from the state hospitals in Johannesburg 
(Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani 
Baragwanath Hospital, Rahima Moosa Mother and Child Hospital) 
and from medical geneticists at the NHLS genetic counselling clinics. A 
small number of cases were referred from other genetic centres around 
SA and from doctors in private practice. Blood samples from the 
patients were sent in with a referral form stating the possible diagnosis 
and in some cases the clinical features observed.
Controls
A total of 200 unrelated and unaffected randomly selected white 
individuals whose DNA samples were taken from the DNA bank in 
the Division of Human Genetics were screened. Of these, 100 were 
selected based on their Afrikaner surnames and screened for the 
c.1100T>C mutation, and a further 100 white controls were screened 
for the c.826C>A FKRP mutation.
Methods
All 45 patients were screened for the c.1100T>C mutation using the 
amplification refractory mutation system-polymerase chain reaction 
(ARMS-PCR) method, and positive results were confirmed on 
Sanger sequencing. The c.826C>A mutation was tested using Sanger 
sequencing only.
Techniques used
ARMS-PCR for FKRP (c.1100T>C) mutation
A multiplex ARMS-PCR method was designed for detection of 
the c.1100T>C mutation using four primers: primers FKRP Ex4-
Control (F-outer) 5ʹ-CGCCCGCCTACCTCTACGAG-3ʹ and FKRP-
ARMS-MUTANT (R-inner) 5ʹ-GCCCACGTCCTCCAAGTTGG-
3ʹ, which amplified the mutant sequence (209 base pairs 
(bp)), and primers FKRP-ARMS-NORMAL (F-inner) 
5ʹ-GGACTACGACGTGGACCTGGGTAT-3ʹ and FKRP Ex4-
Control (R-outer) 5ʹ-AGA AGG GCC ACA GGT CCA CG-3ʹ, 
which amplified the normal sequence (186 bp). An internal control 
fragment of 351 bp was amplified using the FKRP Ex4-Control 
(F-outer) and FKRP Ex4-Control (R-outer) primers. The PCR 
products were separated on a 3% agarose gel.
Sequencing
Sanger sequencing was performed to confirm the presence of the two 
FKRP mutations. Products were run on a ABI 3130xl genetic analyser 
(Applied Biosystems, SA) and results were analysed using the SeqMan 
II application, DNASTAR Lasergene programme (DNASTAR, USA).
c.1100T>C mutation. The FKRP Ex4-Control primers (F-outer 
and R-outer) were used to confirm the ARMS-PCR results on 
patients who tested positive for the c.1100T>C mutation.
c.826C>A mutation. Published primers 3F [5ʹ-ACC AGC CTC 
TTT CTG CAG ACC-3ʹ] and 4R [5ʹ-CCT TCT CCC ATA CGA 
AGC-3ʹ][12] were used to amplify and sequence a 532-bp PCR 
fragment containing the c.826C>A FKRP mutation.
Haplotype analysis
Three dinucleotide short tandem repeat (STR) microsatellite markers 
flanking the FKRP gene, D19S219, D19S412 and D19S606, were 
typed in affected individuals and their families (where available) to 
determine whether the c.1100T>C mutation occurs on a founder 
haplotype.[5] The order of markers is centromere-D19S219-D19S412-
FKRP-D19S606-telomere. The distance between D19S219 and 
D19S606 is ~1.9 MB, with ~0.72 MB between D19S606 and the 
mutation.[1]
Ethics approval
The project protocol was submitted to the Human Research Ethics 
Committee (Medical) of the University of the Witwatersrand, 
Johannesburg, and an ethical clearance certificate was obtained (ref. 
no. M120618)
Results
c.1100T>C and c.826C>A mutation screening
The diagnosis of FKRP muscular dystrophy was confirmed in 10/45 
patients tested (22.2%) and was suggestive in another 2/45 hetero-
zygous patients (4.4%) (Table 1). One heterozygous individual 
with the c.1100T>C mutation was identified in the 100 Afrikaner 
controls tested. None of the 100 white controls tested positive for the 
c.826C>A mutation.
Haplotype analysis
Three flanking dinucleotide STR markers, D19S219, D19S412 and 
D19S606, were used to determine a haplotype, with alleles 182 bp, 
103 bp and 174 bp, respectively, tracking with the c.1100T>C 
mutation. Statistical analysis using Fisher’s exact test showed 
that there were highly significant differences when patients were 
compared with normal controls between the frequencies of alleles 
182 bp, 103 bp and 174 bp, with p-values of <0.0001 for alleles 
182  bp and 103 bp and p=0.0069 for allele 174 bp. This finding 
strongly suggests that a founder haplotype with alleles 182 bp, 
103 bp and 174 bp exists in this population on the chromosome 
carrying the c.1100T>C mutation.
Table 1. Summary of results after testing 45 patients for the 




c.1100T>C homozygote c.1100T>C/c.1100T>C 8* (17.8)
Compound heterozygote c.1100T>C/c.826C>A 2 (4.4)
c.1100T>C heterozygote c.1100T>C/unidentified 1 (2.2)
c.826C>A heterozygote c.826C>A/unidentified 1 (2.2)
c.1100T>C and c.826C>A 
negative
Negative/negative 33 (73.3)
*This includes the two patients tested in the UK.
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Discussion
The FKRP-related muscular dystrophies are caused by different 
mutations in the FKRP gene and may vary in disease severity.[2] The 
marked clinical similarity between LGMD2I and dystrophinopathy 
patients has often resulted in misdiagnosis of an FKRP-related 
muscular dystrophy.[3]
A study by Schwartz et al.[13] in Denmark involved screening for the 
common c.826C>A (p.Leu276Ile) FKRP mutation in 102 European 
patients, who presented with a dystrophinopathy-like phenotype 
but in whom no dystrophin gene rearrangements were identified. 
The study found that ~13% of patients were homozygous for a 
common c.826C>A FKRP mutation and were therefore diagnosed 
with LGMD2I (an FKRP-related muscular dystrophy) and not with a 
dystrophinopathy as had initially been thought.
Similarly, before this study, a novel c.1100T>C (p.Ile367Thr) FKRP 
mutation was first identified in a homozygous state in two unrelated 
Afrikaner patients who were clinically diagnosed with DMD/BMD, 
but in whom no deletions or duplications in the dystrophin gene 
were found. As a result of this finding, a further 43 SA white patients 
suspected of having a dystrophinopathy were screened for this novel 
mutation in this study. Eight patients (17.8%) in total were found to have 
this mutation in a homozygous state and 3 (4.4%) were heterozygous 
for the mutation, suggesting that FKRP mutations are a significant 
cause of disease in patients presenting with a dystrophinopathy-like 
phenotype. Furthermore, since a significant number of patients with 
Afrikaans ancestry carry the c.1100C>T mutation, this mutation has 
not been reported in other populations, and linked marker analysis 
revealed a common haplotype, it is probable that the c.1100C>T 
mutation is a founder mutation in the Afrikaner population. A number 
of founder mutations for other genetic disorders have been identified 
in the SA Afrikaner population.[7-11]
Owing to the suggestive clinical features, the 3 heterozygous 
patients were subsequently screened for the c.826C>A mutation. This 
mutation was found in 2 of the 3, confirming the diagnosis of FKRP.
muscular dystrophy. A diagnosis of FKRP was therefore confirmed 
in 22.2% of the patients screened and suspected in another 4.4% who 
were heterozygous for one of the mutations. It has been reported 
in one study[5] that 4 cases in 10 families (40%) were compound 
heterozygotes and carried another missense mutation in the second 
allele that was said to be pathogenic. In another study that screened 
for the common c.826C>A FKRP mutation in 20 German patients 
from 19 unrelated families, 13 of the 20 patients (65%) were found to 
be homozygous for the mutation and 3 were found to be compound 
heterozygotes carrying a second heteroallelic mutation.[12]
The FKRP c.826C>A mutation appears to be common worldwide, 
with a carrier frequency estimated to be 1 in 300.[12,15] In this current 
study, the carrier frequency of the c.1100T>C mutation was found to 
be approximately 1 in 100. This suggests that the FKRP c.1100T>C 
mutation may be more common in the Afrikaner population of SA 
than elsewhere. The c.826C>A mutation was not found in 100 control 
individuals tested in the SA population, but was found in the patient 
cohort, indicating that this is not a particularly common mutation in 
SA, but does occur.
Conclusion
This study shows that FKRP-related muscular dystrophy accounts 
for a significant number of patients with a phenotype suggestive of 
a dystrophinopathy, and that the mutation c.1100T>C is likely to be 
a founder mutation in the SA Afrikaner population. The c.826C>A 
was identified in compound heterozygous form, suggesting that 
this common European mutation also occurs in SA white patients. 
Patients of possible Afrikaans ancestry with a dystrophinopathy 
phenotype who test negative for DMD/BMD mutations on MLPA 
should be screened for FKRP mutations. The findings emphasise the 
need for caution in the diagnosis of dystrophinopathy-like disorders, 
to prevent misdiagnosis and inaccurate genetic counselling. Since 
FKRP-related muscular dystrophy is an autosomal recessive and not 
an X-linked disorder, the risks to relatives are significantly different. 
The knowledge derived from this study will be very useful in 
ensuring more accurate diagnostic, carrier and prenatal testing for SA 
families with dystrophinopathy-like muscular dystrophies.
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